{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:02:17Z","timestamp":1785466937815,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"DOI":"10.7759\/cureus.113689","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:44:37Z","timestamp":1785465877000},"source":"Crossref","is-referenced-by-count":0,"title":["Proton Therapy for Muscle-Invasive Bladder Cancer: Outcomes from the Multicenter Proton Collaborative Group PCG 001-09 Registry Trial"],"prefix":"10.7759","author":[{"given":"Caroline","family":"Oska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur J","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur K","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit M","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Isabelle","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpi D","family":"Thukral Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Durci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber I","year":"2023","unstructured":"Jubber I, Ong S, Bukavina L, et al.. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023, 84:176-90. 10.1016\/j.eururo.2023.03.029","journal-title":"Eur Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein JP","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al.. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001, 19:666-75. 10.1200\/JCO.2001.19.3.666","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(02)01650-3","article-title":"Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer","volume":"60","author":"Shipley WU","year":"2002","unstructured":"Shipley WU, Kaufman DS, Zehr E, et al.. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002, 60:62-7. 10.1016\/s0090-4295(02)01650-3","journal-title":"Urology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1491","article-title":"Errata","volume":"33","year":"2015","unstructured":"Errata. J Clin Oncol. 2015, 33.814. 10.1200\/JCO.2015.61.1491","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley WU","year":"1998","unstructured":"Shipley WU, Winter KA, Kaufman DS, et al.. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998, 16:3576-83. 10.1200\/JCO.1998.16.11.3576","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman DS","year":"2009","unstructured":"Kaufman DS, Winter KA, Shipley WU, et al.. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009, 73:833-7. 10.1016\/j.urology.2008.09.036","journal-title":"Urology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-6-471","article-title":"The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I\/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response","volume":"5","author":"Kaufman DS","year":"2000","unstructured":"Kaufman DS, Winter KA, Shipley WU, et al.. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I\/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000, 5:471-6. 10.1634\/theoncologist.5-6-471","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou JA","year":"2009","unstructured":"Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009, 27:4055-61. 10.1200\/JCO.2008.19.5776","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart RA","year":"2013","unstructured":"Huddart RA, Hall E, Hussain SA, et al.. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004). Int J Radiat Oncol Biol Phys. 2013, 87:261-9. 10.1016\/j.ijrobp.2013.06.2044","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5455\/aim.2013.21.211-212","article-title":"Comparison of 3D CRT and IMRT tratment plans","volume":"21","author":"Bakiu E","year":"2013","unstructured":"Bakiu E, Telhaj E, Kozma E, Ru\u00e7i F, Malkaj P. Comparison of 3D CRT and IMRT tratment plans. Acta Inform Med. 2013, 21:211-2. 10.5455\/aim.2013.21.211-212","journal-title":"Acta Inform Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.07.017","article-title":"The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A phase II single-centre prospective study","volume":"32","author":"Tan MP","year":"2020","unstructured":"Tan MP, Harris V, Warren-Oseni K, et al.. The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A phase II single-centre prospective study. Clin Oncol (R Coll Radiol). 2020, 32:93-100. 10.1016\/j.clon.2019.07.017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2013.041","article-title":"Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer","volume":"5","author":"Colaco RJ","year":"2014","unstructured":"Colaco RJ, Nichols RC, Huh S, et al.. Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. J Gastrointest Oncol. 2014, 5:3-8. 10.3978\/j.issn.2078-6891.2013.041","journal-title":"J Gastrointest Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101638","article-title":"Proton beam therapy in rectal cancer: a systematic review and meta-analysis","volume":"38","author":"Fok M","year":"2021","unstructured":"Fok M, Toh S, Easow J, Fowler H, Clifford R, Parsons J, Vimalachandran D. Proton beam therapy in rectal cancer: a systematic review and meta-analysis. Surg Oncol. 2021, 38:101638. 10.1016\/j.suronc.2021.101638","journal-title":"Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.14338\/IJPT-17-00027.1","article-title":"Proton therapy reduces normal tissue dose in extended-field pelvic radiation for endometrial cancer","volume":"4","author":"Xu MJ","year":"2018","unstructured":"Xu MJ, Maity A, Vogel J, Kirk M, Zhai H, Both S, Lin LL. Proton therapy reduces normal tissue dose in extended-field pelvic radiation for endometrial cancer. Int J Part Ther. 2018, 4:1-11. 10.14338\/IJPT-17-00027.1","journal-title":"Int J Part Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrad027","article-title":"Proton beam therapy for muscle-invasive bladder cancer: a systematic review and analysis with Proton-Net, a multicenter prospective patient registry database","volume":"64","author":"Araya M","year":"2023","unstructured":"Araya M, Ishikawa H, Nishioka K, et al.. Proton beam therapy for muscle-invasive bladder cancer: a systematic review and analysis with Proton-Net, a multicenter prospective patient registry database. J Radiat Res. 2023, 64:i49-58. 10.1093\/jrr\/rrad027","journal-title":"J Radiat Res"},{"key":"ref16","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD. U.S. Department of Health and Human Services, National Institutes of Health; Published November 27. (2017). https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref17","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al.. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-55.","journal-title":"Am J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(00)00772-0","article-title":"Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors","volume":"48","author":"Pirzkall A","year":"20001","unstructured":"Pirzkall A, Carol M, Lohr F, H\u00f6ss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys. 20001, 48:1371-80. 10.1016\/s0360-3016(00)00772-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2349\/biij.2.1.e19","article-title":"Intensity modulated radiotherapy: advantages, limitations and future developments","volume":"2","author":"Cheung K","year":"2006","unstructured":"Cheung K. Intensity modulated radiotherapy: advantages, limitations and future developments. Biomed Imaging Interv J. 2006, 2:e19. 10.2349\/biij.2.1.e19","journal-title":"Biomed Imaging Interv J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.11.005","article-title":"Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer","volume":"88","author":"Turgeon GA","year":"2014","unstructured":"Turgeon GA, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, Kassouf W. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014, 88:326-31. 10.1016\/j.ijrobp.2013.11.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s13566-019-00411-0","article-title":"Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization","volume":"8","author":"Sherry AD","year":"2019","unstructured":"Sherry AD, Stewart A, Luo G, Kirschner AN. Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization. J Radiat Oncol. 2019, 8:395-403. 10.1007\/s13566-019-00411-0","journal-title":"J Radiat Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","volume":"87","author":"Huddart R","year":"2025","unstructured":"Huddart R, Hafeez S, Griffin C, et al.. Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial. Eur Urol. 2025, 87:60-70. 10.1016\/j.eururo.2024.09.006","journal-title":"Eur Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.010.10529","article-title":"Proton therapy in clinical practice","volume":"30","author":"Liu H","year":"2011","unstructured":"Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer. 2011, 30:315-26. 10.5732\/cjc.010.10529","journal-title":"Chin J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/15330346070060S404","article-title":"Absorption characteristics of protons and photons in tissue","volume":"6","author":"Dicello JF","year":"2007","unstructured":"Dicello JF. Absorption characteristics of protons and photons in tissue. Technol Cancer Res Treat. 2007, 6:25-9. 10.1177\/15330346070060S404","journal-title":"Technol Cancer Res Treat"},{"key":"ref25","unstructured":"NCCN Bladder Cancer Guidelines (Version 2.2026, published June 22, 2026). (2026). Accessed. August 7, 2026: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2017.11.005","article-title":"Robust proton treatment planning: physical and biological optimization","volume":"28","author":"Unkelbach J","year":"2018","unstructured":"Unkelbach J, Paganetti H. Robust proton treatment planning: physical and biological optimization. Semin Radiat Oncol. 2018, 28:88-96. 10.1016\/j.semradonc.2017.11.005","journal-title":"Semin Radiat Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin DF","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al.. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021, 384:2102-14. 10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010572","article-title":"Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)","volume":"13","author":"Galarza Fortuna GM","year":"2025","unstructured":"Galarza Fortuna GM, Grass D, Maughan BL, et al.. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer. 2025, 13:e010572. 10.1136\/jitc-2024-010572","journal-title":"J Immunother Cancer"},{"key":"ref29","article-title":"Phase Ib\/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer. ClinicalTrials.gov identifier NCT06470282. Published June 19","volume":"1","author":"Koshkin","year":"2017","unstructured":"Koshkin, V. Phase Ib\/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer. ClinicalTrials.gov identifier NCT06470282. Published June 19. 2017, 1:2023-3."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103620","article-title":"Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials","volume":"9","author":"Koide Y","year":"2024","unstructured":"Koide Y, Kodaira T. Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials. ESMO Open. 2024, 9:103620. 10.1016\/j.esmoop.2024.103620","journal-title":"ESMO Open"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2025.101926","article-title":"Safety of combining radiation therapy and antibody drug conjugates in advanced urothelial and other cancers","volume":"11","author":"Lock D","year":"2026","unstructured":"Lock D, Soni YS, Hwang L, et al.. Safety of combining radiation therapy and antibody drug conjugates in advanced urothelial and other cancers. Adv Radiat Oncol. 2026, 11:101926. 10.1016\/j.adro.2025.101926","journal-title":"Adv Radiat Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10455.x","article-title":"Factors influencing post-recurrence survival in bladder cancer following radical cystectomy","volume":"109","author":"Mitra AP","year":"2012","unstructured":"Mitra AP, Quinn DI, Dorff TB, et al.. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012, 109:846-54. 10.1111\/j.1464-410X.2011.10455.x","journal-title":"BJU Int"},{"key":"ref33","article-title":"Outcome of urinary bladder cancer after combined therapies","volume":"9","author":"Anghel RM","year":"2016","unstructured":"Anghel RM, Gales LN, Trifanescu OG. Outcome of urinary bladder cancer after combined therapies. J Med Life. 2016, 9:153-9.","journal-title":"J Med Life"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503971-proton-therapy-for-muscle-invasive-bladder-cancer-outcomes-from-the-multicenter-proton-collaborative-group-pcg-001-09-registry-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:44:40Z","timestamp":1785465880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503971-proton-therapy-for-muscle-invasive-bladder-cancer-outcomes-from-the-multicenter-proton-collaborative-group-pcg-001-09-registry-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.113689","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}